anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,381-130,440 of 319,975

filter-aware
53
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
54
The slide emphasizes the credibility of the interviewees by linking them to specific published papers (C601 and C602).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
55
The slide uses a 'villain_critique' approach by leveraging an expert's authority to discredit the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
56
The slide uses direct quotes from an expert to highlight risks of cardiac events, seizures, and trial design flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
57
The slide uses direct quotes from an expert to undermine the viability of the company's drug formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
58
This slide functions as a 'villain_critique' or 'expose_contradiction' regarding the drug's clinical reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
59
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
60
The slide uses direct quotes from an expert to discredit a competitor's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
61
This slide presents expert testimony/critique from a trial investigator, serving as a 'villain_critique' or 'expose_contradiction' style slide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
62
The slide uses a 'nominee_bio' structure to present a 'villain_critique' or 'expose_contradiction' narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
63
The slide uses direct quotes to expose potential data omissions and competitive disadvantage.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
64
The slide uses direct quotes from an expert to undermine the commercial viability and clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
65
The slide uses direct quotes from a trial investigator to undermine the drug's efficacy and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
66
This slide is part of a series of 'investigator' profiles used to build a case against a company's clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
67
The slide presents critical expert feedback on drug formulation and safety protocols.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
68
The slide uses a 'villain' or 'expert critic' framing to undermine the credibility of a clinical trial and its associated drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
69
The slide uses direct quotes from an expert to undermine the value proposition of the subject company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
70
The slide uses a series of bullet points to contrast public posturing with private admissions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
71
The slide uses specific quotes from an investigator to undermine the validity of clinical trial results and highlight potential adverse events.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
72
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
73
The slide emphasizes the credibility and breadth of the expert sample to validate the subsequent findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
74
The slide uses direct quotes to undermine the credibility of the drug's approval and market demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
75
The slide uses direct quotes from an expert consultation to undermine the company's product launch and clinical efficacy claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
76
The slide uses a direct quote to highlight medical risks that could limit the drug's market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
77
The slide serves as a negative testimonial/expert critique of the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
78
The slide uses direct quotes to highlight a lack of industry awareness and clinical skepticism regarding the drug's mechanism and efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
81
The slide captures qualitative feedback from a medical expert, highlighting low adoption rates and negative sentiment toward the company's sales approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
82
The slide uses direct quotes to undermine the company's marketing claims and highlight physician concerns regarding side effects like diabetes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
83
The slide uses direct quotes from an expert to undermine the company's clinical narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
84
The slide uses direct quotes to undermine the company's marketing claims about drug efficacy and differentiation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
85
The slide uses direct quotes to highlight the physician's lack of confidence in the drug and his perception of external pressure from patient advocacy groups.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
86
The slide uses direct quotes to undermine the credibility of the drug's clinical narrative and the company's influence on investigators.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
88
The slide highlights the gap between physician prescribing behavior (driven by patient pressure) and their actual clinical belief in the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
89
This slide presents qualitative interview data from a medical expert to undermine the credibility of a drug and a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
92
The slide presents qualitative expert feedback from a medical professional regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
93
The slide presents qualitative feedback from a medical expert, highlighting concerns about diabetes risk and comparing the drug to the Aduhelm controversy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
96
The slide presents a qualitative critique from a medical professional, highlighting skepticism regarding clinical efficacy and administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
97
The slide uses direct quotes to undermine the clinical value and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
98
The slide uses a direct quote to highlight the physician's negative sentiment regarding the drug's value proposition versus the administrative effort required.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
99
The slide uses direct quotes to highlight the expert's negative sentiment and concerns regarding side effects and reimbursement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
101
The slide uses direct quotes to expose contradictions in the drug's adoption and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
103
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
104
The seesaw diagram is a visual metaphor for the mechanism of action and its unintended side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
105
The slide uses a direct comparison of drug mechanisms to challenge the target company's safety claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
107
The slide uses red boxes to draw attention to the specific data points being compared.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
109
The slide uses direct quotes from medical experts to highlight a potential flaw in the company's clinical approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
110
The slide uses a Q&A transcript format to highlight specific patient cases that suggest a severe, long-term adverse effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit